Best Life Sciences Companies in Nouvelle Aquitaine, France
The 59 best Life Sciences companies in Nouvelle Aquitaine, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: TreeFrog Therapeutics.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Nouvelle Aquitaine
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TreeFrog Therapeutics Developer of stem cells and organoids using proprietary technology 62Patents top 21%Innovation top 22%Funding top 26%Moat top 29% All 10 signals ▾Patentstop 21% Innovationtop 22% Fundingtop 26% Moattop 29% Growthtop 35% Markettop 48% Talentbottom 49% Globalbottom 43% Techbottom 25% Newsbottom 22% Patents: 148 patents matched (strict assignee match) · 143 filings since 2022 vs 5 in 2017-21 Innovation: 148 patents (top 18% of patent-holders) · 143 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $84M | 13 mo ago | 110 | Kevin Alessandri Co-Founder & CTO | WordPressMySQLPHP+11 | Series B | 148 patents Engineered neural tissue therapeutics and microfluidic cell‑encapsulation platforms for regenerative medicine | 1 launch |
| 2 | Medicrea Surgical devices for spinal and orthopedic surgeries | $83M | 91 mo ago | 175 | Denys Sournac Founder | Javaparticles.jsASP.NET Boilerplate+10 | Acquired | 289 patents Spinal fixation and intervertebral disc replacement devices for vertebrae surgery | — |
| 3 | FineHeart Developer of an implantable cardiovascular device for treating heart failures 60Funding top 23%Moat top 26%Growth top 28%Patents top 33% All 9 signals ▾Fundingtop 23% Moattop 26% Growthtop 28% Patentstop 33% Innovationtop 34% Newstop 36% Marketbottom 45% Globalbottom 43% Techbottom 34% Funding: Raised $51.9M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 162 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $52M | 6 mo ago | 50 | — | WordPress Block EditorElementorWordPress+21 | Series C | 162 patents Implantable cardiac assist devices and transcutaneous power systems for heart support | — |
| 4 | Fermentalg Innovating with algae for sustainable solutions in nutrition and environmental impact | $30M | 54 mo ago | 62 | — | WordPressMySQLPHP+20 | Public | 387 patents Microalgal biotech producing DHA oils, pigments, glycogen-derived products, and cosmetic extracts | 1 launch |
| 5 | Hyprevention Developer of implantable orthopedic medical devices | $21M | 27 mo ago | 8 | — | — | Series B | 38 patents Orthopedic bone fixation implants for fractured and non‑fractured bones | — |
| 6 | Aelis Farma Developer of small molecule drugs targeting CB1 receptor for CNS diseases | $14M | 65 mo ago | 22 | Pier Piazza CEO | Node.jsGSAPVue.js+10 | Public | 61 patents Synthetic pregnane analogs for neuropharmacological treatment of cognitive and cannabinoid disorders | — |
| 7 | YSOPIA Bioscience Developer of microbiome-based therapies for treating diseases like obesity, metabolic, inflammatory & others | $13M | 82 mo ago | 8 | — | — | Series C | — | — |
| 8 | Germitec Provider of UV-C high-level disinfection systems for ultrasound probes. | $12M | 16 mo ago | 48 | Clement Deshays Founder & CEO | WebflowCloudflare TurnstileHSTS+13 | Series B | 117 patents Medical device disinfection chambers and processes for sterilizing instruments and equipment. | — |
| 9 | Advanced BioDesign Provides services in immunotechnology | $10M | 76 mo ago | 20 | — | — | Series A | 121 patents Novel aminothiolester anticancer agents and delivery systems | — |
| 10 | Satelia Provider of a device for cardiac health monitoring | $10M | 44 mo ago | 81 | Nicolas PAGES Co-Founder | Apple iCloud MailGoogle WorkspacePHP+14 | Series A | — | — |
| 11 | Implanet Developer of implants for orthopedic surgery | $10M | 104 mo ago | 42 | — | WordPressMySQLPHP+16 | Public | 121 patents Spinal vertebra fixation systems and bone band attachment devices for orthopedic surgery. | — |
| 12 | Poietis Laser-assisted 3D bioprinting technology | $9M | 46 mo ago | 38 | — | WordPressMySQLPHP+21 | Series A | 65 patents Laser-based 3D bioprinting of living tissues and cellular constructs | — |
| 13 | Meccellis Developer of biological implants based on the acellular dermis | $8M | 43 mo ago | — | Anthony Peres CEO | — | Series B | — | 1 partnership |
| 14 | Biomatlante Biphasic synthetic bone grafts for bone regeneration using MBCP Technology. | $5M | 114 mo ago | 32 | — | JoomlaApple iCloud MailMicrosoft 365+14 | Acquired | 38 patents Bone regeneration scaffolds: hydrogels, dehydrated granules, contrast‑enhanced bone substitutes. | — |
| 15 | Activ Inside Develops and markets natural and innovative botanical active ingredients | $4M | 66 mo ago | 60 | Benoit Lemaire CEO - Business & Marketing VP | WordPressMySQLPHP+17 | Series A | 10 patents Saffron‑derived prebiotic and antioxidant nutraceutical compositions for gut health | 3 launchs |
| 16 | Glycode Technology platform for producing recombinant therapeutic glycoproteins | $4M | 197 mo ago | — | Christophe Javaud CEO | — | Deadpooled | 20 patents Yeast-based recombinant glycoengineering for homogeneous therapeutic glycoprotein production | — |
| 17 | Rebrain Developer of therapeutics for the treatment of neurodegenerative diseases | $4M | 27 mo ago | 4 | Emmanuel Cuny Co-Founder | WordPressMySQLPHP+14 | Seed | — | 1 award |
| 18 | MitoProd Developer of technology for the production of ribonucleic acids | $3M | — | — | Guillaume Plane Founder & CEO | — | Deadpooled | — | — |
| 19 | Seekyo Developer of selective cancer drug delivery systems | $721K | 63 mo ago | 9 | Oury Chetboun Co-Founder & CEO | — | Seed | 10 patents Cancer gene‑therapy vectors and prodrug delivery systems using heterocyclic compounds | 2 launchs |
| 20 | B-cell design Develops immuno therapeutic solution for diseases | $705K | 133 mo ago | 5 | Gael Champier Co-Founder | — | Seed | 25 patents Therapeutic and diagnostic anti‑CEA monoclonal antibodies and chimeric antibody production | — |
| 21 | ABO Diag SAS Provider of blood analyzers | $601K | 161 mo ago | 2 | — | — | Acqui-Hired | — | — |
| 22 | KAMAX Innovative System Realtime polarimetry imaging to detect cancer cells | $513K | 97 mo ago | 4 | Olivier Baudet CEO & President | — | Seed | — | 2 expansions |
| 23 | Oncomedics Provider of a diagnostic test for the personalization of cancer treatment | $508K | 192 mo ago | — | Christophe Lautrette Founder & CEO | Cart FunctionalityBootstrapSvelte+8 | Seed | 11 patents Microbiome sample decontamination/culture and quantitative cell‑aggressiveness assay technologies | — |
| 24 | ECM Ultrasound scanners for clinical applications | $298K | 125 mo ago | 26 | — | — | Funding Raised | 51 patents Advanced heat‑treatment and crystal growth equipment for metal alloy processing | — |
| 25 | Cordouan Technologies Developer of nanocharacterization solutions for the nanomaterial industry | $286K | 124 mo ago | 9 | Mathias Pennec CEO | WordPressMySQLPHP+16 | Funding Raised | 11 patents Electroacoustic particle sizing and characterization of colloidal solutions | 1 launch |
| 26 | Ademtech Superparamagnetic nanoparticles for biological applications | $180K | 188 mo ago | 23 | Bernard Plichon CEO | JimdoMustacheModernizr+10 | Series A | — | 1 expansion |
Top 12 Life Sciences companies in Nouvelle Aquitaine
#1
Series C · Pessac, Nouvelle Aquitaine · founded 2010 · 50 employees$51.9Mraised▾
Developer of an implantable cardiovascular device for treating heart failures. The device provides long-term circulatory assistance. The I.C.O.M.S. (Implantable Cardiac Output Management System) is synchronized to heart innate contraction and helps to manage heart failure disease.
- Jan 2026Series C$40.8M
- Jan 2026Grant (prize money)$56M
- Oct 2022Grant (prize money)$2.4M
- 2022Grant (prize money)$19.8M
#2
Series B · Talence, Nouvelle Aquitaine · founded 2018 · 110 employees$84.2Mraised▾
TreeFrog Therapeutics is developing stem cells and organoids using proprietary technology to enable the development of cell therapies. It enables the younger cells to mitigate mutational risks. They have developed organoids from pluripotent stem cells.
- May 2025Venture Debt$34.2M
- Oct 2021Grant (prize money)$57.8K
- Sep 2021Series B$75.6M
- Nov 2019Grant (prize money)$2.6M
#3
Series B · Bordeaux, Nouvelle Aquitaine · founded 2005 · 48 employees$11.6Mraised▾
{}
- Feb 2025Series B$30M
- May 2022Series B$11.6M
#4
Series B · Pessac, Nouvelle Aquitaine · founded 2010 · 8 employees$21.4Mraised▾
Developer of implantable orthopedic medical devices. The products of the company include Y-STRUT an implantable medical device for internal fixation of proximal femur of patients at risk of osteoporotic fracture and for impeding pathological fracture and V-STRUT is a Percutaneous Vertebral Augmentation device for the treatment of the vertebral fracture.
- Apr 2024Series B$16.1M
- Mar 2022Series A$4.5M
- Sep 2020Series A—
- Dec 2015Seed$824K
#5
Acquired · La Rochelle, Nouvelle Aquitaine · founded 1990 · 175 employees$83.1Mraised▾
Medicrea develops products for spinal and orthopedic surgery. The company operates internationally covering USA, France etc. The company's products include PASS range (PASS LP and LigaPass 2.0); Cervical range (C-Jaws, Impix-C, Impix-Manta) which are used in the treatment of spinal pathologies such as scoliosis, spondylolythesis, and spinal fixations. The company offers TH-LUMBAR range of products in France and other countries except USA. The company also manufactures 3D printed spine implants. The products are FDA cleared and CE marked.
- Nov 2018Conventional Debt$30M
- Jul 2018Post IPO$3.6M
- Dec 2017Post IPO$8.5M
- Jun 2017Post IPO$14.6M
#6
Public · Libourne, Nouvelle Aquitaine · founded 2005 · 62 employees$30.3Mraised▾
Innovating with algae for sustainable solutions in nutrition and environmental impact. The company focuses on harnessing the power of microalgae to create a range of sustainable products. These include vegan omega , natural colors, natural antioxidants, and proteins for aquafeed and pet food. The company is committed to sustainability, demonstrated through certifications and a focus on social responsibility. Their approach includes screening strains, fermentation, and industrial scale-up. The company's work extends to environmental solutions through CarbonWorks, reflecting a commitment to a greener future. They offer solutions in nutrition and environmental impact, positioning themselves as a key player in the bio-based industry. The company is dedicated to research, development, and the application of microalgae across various sectors.
- Dec 2021Post IPO—
- Apr 2014Post IPO$55.8M
- Sep 2013Series B$16.2M
- 2011Series B$6.9M
#7
Seed · Pessac, Nouvelle Aquitaine · founded 2021 · 4 employees$4Mraised▾
Developer of therapeutics for the treatment of neurodegenerative diseases. The company develops precise targeting technology for Deep Brain Stimulation using an algorithm based on Artificial Intelligence that helps neurosurgeons identifying brain regions to operate on patients with Parkinson’s disease and essential tremor.
- Mar 2024Seed$4M
#8
Series A · Pessac, Nouvelle Aquitaine · founded 2014 · 38 employees$9Mraised▾
Poietis develops and produces human, customized tissues using 4D bioprinting for pharmaceutical and cosmetic applications as well as regenerative medicine. Complex 3D tissues are obtained by high resolution Laser-Assisted Bioprinting. Poietis is the result of over 10 years of research conducted at INSERM (France’s National Institute for Health and Medical Research) and the University of Bordeaux. Poietis’ pioneering laser 3D printing technology stands out because it allows them to assemble live cells into pre-determined 3D structures with a resolution of up to 20 micrometers. The company has signed a major R&D agreement with leading chemical firm BASF to develop advanced 3D printed skincare applications.
- Sep 2022Grant (prize money)$507.2K
- Jan 2020Grant (prize money)$1.6M
- Oct 2018Grant (prize money)$749.8K
- Mar 2018Series A$6.2M
#9
Series A · Bordeaux, Nouvelle Aquitaine · founded 2017 · 81 employees$9.9Mraised▾
Provider of a device for cardiac health monitoring. The company offers Satelia cardio for the telemonitoring of heart failure patients and also offers an alert system that allows the medical team to identify patients showing a possible deterioration of health and to view the history of teletransmissions.
- Oct 2022Series A$9.9M
#10
Series B · La Rochelle, Nouvelle Aquitaine · founded 2011$8.2Mraised▾
Developer of biological implants based on the acellular dermis. The product Cellis is a collagen matrix for soft tissue repair, Cellis Breast is a surgical membrane made of the porcine dermis for breast reconstruction, and Cellis Dental is a cell-free, collagen matrix used as a surgical membrane in soft tissue repairs.
- Nov 2022Series B$8.2M
#11
Public · Bordeaux, Nouvelle Aquitaine · founded 2013 · 22 employees$14Mraised▾
Developer of small molecule drugs targeting CB1 receptor for CNS diseases. The company's platform is based on the neurosteroid pregnenolone is an endogenous “signaling specific negative modulator” of the CB1 receptor. The company is developing CB1 signaling-specific inhibitors (AEF0117) to treat cannabis abuse. AEF0118 is the second lead compound for metabolic and fibrotic diseases.
- Feb 2021Grant (prize money)$4.1M
- Dec 2019Seed$12.2M
- Mar 2014Seed$1.8M
#12
Series C · Bordeaux, Nouvelle Aquitaine · founded 2010 · 8 employees$13Mraised▾
YSOPIA bioscience is a developer of microbiome-based therapies for treating diseases like obesity, metabolic, inflammatory & others. It is a gut microbiome-based drug discovery platform that uses bacterial strains to deliver microbiome-based therapies in obesity, metabolic disorders, and mood disorders. Its product Yso1 is a development project that uses Christensenella minuta as a novel therapy to treating obesity and metabolic disorders. It provides Yso2 & Yso3 that uses beneficial bacteria such as Christensenella by developing single strain live biotherapeutic products to treat patients suffering from inflammatory diseases. The drug Yso4 helps in the treatment of the gut-brain axis for the treatment of mood disorders.
- Sep 2019Series C$5.4M
- Sep 2019Grant (prize money)$1.4M
- Sep 2017Series C$7.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
- Centre NAT RECH Scient10056
- INST NAT Sante RECH MED8306
- Sanofi3990
- Pasteur Institut3426
- Agronomique INST NAT RECH1335
- Cellectis1320
- PF Medicament1204
- Commissariat Energie Atomique1156
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.